JLE

Annales de Biologie Clinique

MENU

Thrombin time and anti-IIa dabigatran's activity: hypothesis of thrombin time's predictive value Volume 73, issue 5, Septembre-Octobre 2015

Tables

Authors
Laboratoire d’hématologie et immunologie, Centre Hospitalier, Le Mans, France
* Tirés à part

Dabigatran etexilate (Pradaxa®) is a new oral anticoagulant, competitive inhibitor, selective, fast, direct and reversible of thrombin. Dabigatran has an impact on a large panel of used coagulation tests. There is no relationship between thrombin time's lengthening and anti-IIa activity. This study defines thrombin time's predictive value, when its time is normal. The result of negative value is 97,6%. 255 patients were studied between January 2013 and July 2014. Thrombin time and anti-IIa activity were dosed for each patient. This study can be an assistant for therapeutic decision for laboratories without specialized test.